Praktikabilität und Leistungsfähigkeit von E-Health-Anwendungen bei der Erhebung von Patient Reported Outcomes: Forschungsstand und -bedarf

Graf, Joachim; Moreno, Beatrice; Wallwiener, Markus; Menzel, K; Brucker, Sara Y.; Simoes, Elisabeth

doi:10.1055/s-0044-100037

Cited by 7 publications

(7 citation statements)

References 43 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, a corresponding analysis in relation to differences and correlations between the paper-based version of FACT-B and newly developed Web-based tools are of great importance. It can be assumed that many aspects (ie, sociodemographic aspects, technical skills, health condition, and, perhaps, design specifics of the ePRO tool) may influence both patients’ willingness to use the tool and their response behavior, which underlines the need for reliability analyses [10,24,35-37]. However, almost no scientific studies have dealt with the reliability of ePRO questionnaires.…”

Section: Discussionmentioning

confidence: 99%

“…Although paper-based surveys of PRO still predominate because there are only a few reliable and validated ePRO questionnaires, numerous projects have evaluated the feasibility and acceptance of HRQoL in the ePRO measurement in the last few years [29-34]. Nevertheless, knowledge regarding patients’ acceptance, feasibility, and barriers remains limited [35], especially because hurdles might exist in relation to health status, technical skills, and socioeconomic aspects, which could influence both patients´ willingness to use ePRO and their response behavior [10,36,37]. Although studies have already demonstrated a potential equivalence between some paper-based PRO and ePRO, the reliability of ePRO questionnaires should be verified so as not to endanger the validity of ePRO surveys [10,36-40].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study

Matthies¹,

Taran²,

Keilmann³

et al. 2019

J Med Internet Res

Self Cite

View full text Add to dashboard Cite

BackgroundThe most frequent malignant disease in women is breast cancer. In the metastatic setting, quality of life is the primary therapeutic goal, and systematic treatment has only a limited effect on survival rates; therefore, the concept of the health-related quality of life (HRQoL) and measurement of patient-reported outcomes (PROs) are gaining more and more importance in the therapy setting of diseases such as breast cancer. One of the frequently used questionnaires for measuring the HRQoL in patients with breast cancer is the Functional Assessment of Cancer Therapy-Breast (FACT-B). Currently, paper-based surveys still predominate, as only a few reliable and validated electronic-based questionnaires are available. ePRO tools for the FACT-B questionnaire with proven reliability are missing so far.ObjectiveThe aim of this study was to analyze the reliability of tablet-based measurement of FACT-B in the German language in adjuvant (curative) and metastatic breast cancer patients.MethodsPaper- and tablet-based questionnaires were completed by a total of 106 female adjuvant and metastatic breast cancer patients. All patients were required to complete the electronically based (ePRO) and paper-based version of the FACT-B. A frequency analysis was performed to determine descriptive sociodemographic characteristics. Both dimensions of reliability (parallel forms reliability using Wilcoxon test and test of internal consistency using Spearman ρ) and agreement rates for single items, Kendall tau for each subscale, and total score were analyzed.ResultsHigh correlations were shown for both dimensions of reliability (parallel forms reliability and internal consistency) in the patients’ response behavior between paper-based and electronically based questionnaires. Regarding the reliability test of parallel forms, no significant differences were found in 35 of 37 single items, while significant correlations in the test for consistency were found in all 37 single items, in all 5 sum individual item subscale scores, as well as in total FACT-B score.ConclusionsThe ePRO version of the FACT-B questionnaire is reliable for patients with breast cancer in both adjuvant and metastatic settings, showing highly significant correlations with the paper-based version in almost all questions all subscales and the total score.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study

Matthies¹,

Taran²,

Keilmann³

et al. 2019

J Med Internet Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although paperbased surveys of PRO still predominate because there are only a few reliable and validated ePRO questionnaires, numerous projects have evaluated feasibility and acceptance of HRQoL in ePRO measurement in the last few years [29][30][31][32][33][34]. Nevertheless, knowledge regarding patient acceptance, feasibility, and barriers remains limited [35], especially since hurdles might exist in relation to health status, technical skills, and socioeconomic aspects, which could influence both patients´ willingness to use ePRO and their response behavior [10,36,37]. Although studies have already demonstrated a potential equivalence between some paper-based PRO and ePRO, reliability of ePRO questionnaires should be verified so as not to endanger the validity of ePRO surveys [10,[36][37][38][39][40].…”

Section: Electronic Measurement Of Patient-reported Outcomesmentioning

confidence: 99%

“…Thus, a corresponding analysis in relation to differences and correlations between the paper-based vision of FACT-B and newly developed online tools are of great importance. It can be assumed that many aspects (i.e., sociodemographic aspects, technical skills, health condition, and perhaps design specifics of the ePRO tool) may influence both patients' willingness to use the tool and their response behavior, which underlines the need for reliability analyses [10,24,[35][36][37]. However, almost no scientific studies have dealt with the reliability of ePRO questionnaires.…”

Section: Comparison With Prior Workmentioning

confidence: 99%

An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study (Preprint)

Matthies¹,

Taran²,

Keilmann³

et al. 2018

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundThe most frequent malignant disease in women is breast cancer. In the metastatic setting, quality of life is the primary therapeutic goal and systematic treatment has only limited effect on survival rates; therefore, the concept of Health-related Quality of Life (HRQoL) and measurement of Patient Reported Outcomes (PRO) is gaining more and more importance in the therapy setting of diseases such as breast cancer. One of the frequently used questionnaires for measuring HRQoL in breast cancer patients is the Functional Assessment of Cancer Therapy -Breast (FACT-B). Currently, paperbased surveys still predominate as only a few reliable and validated electronic-based questionnaires are available. EPRO tools of the FACT-B questionnaire with proven reliability are missing so far.

show abstract

“…In recent years an emphasis has been made on patient-reported outcomes (PRO) as a means of collecting HRQoL data. PROs are characterized by the fact that several validated questionnaires are used simultaneously for HRQoL measurement in order to balance the respective subjectivity [8].…”

Section: Introductionmentioning

confidence: 99%

Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study

Brusniak¹,

Feißt²,

Sebesteny³

et al. 2021

JMIR Cancer

Self Cite

View full text Add to dashboard Cite

Background Health-related quality of life (HRQoL) is used to evaluate the treatment of metastatic breast cancer. In a long-term therapy setting, HRQoL can be used as an important benchmark for treatment success. With the help of digital apps, HRQoL monitoring can be extended to more remote areas and be administered on a more frequent basis. Objective This study aims to evaluate 3 common HRQoL questionnaires in metastasized breast cancer in terms of TTD in a digital, web-based setting. We further aim to examine the development of the HRQoL in different systemic treatment groups in each of these evaluation instruments. Methods A total of 192 patients with metastatic breast cancer were analyzed in this bicentric prospective online cohort study at two German university hospitals. Patients completed questionnaires on HRQoL (EuroQol Visual Analog Scale [EQ-VAS], EuroQol 5 Dimension 5 Level [EQ-5D-5L], European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 item [EORTC QLQ-C30]) via an online platform over a 6-month period. Treatment schedules and medical history were retrieved from medical records. Unadjusted Cox regression analysis on treatment-related factors was performed. We conducted subgroup analyses in regard to TTD events between different treatments. Results The EQ-VAS showed a higher rate of deterioration after 8 weeks (84/179, 46.9%) than the EQ-5D-5L (47/163, 28.8%) and EORTC QLQ-C30 (65/176, 36.9%). Unadjusted Cox regression revealed significant connections between known metastases in the liver (P=.03, HR 1.64, 95% CI 1.06-2.52) and pleura (P=.04, HR 0.42, 95% CI 0.18-0.96) in the EQ-VAS. Significant relations between EQ-VAS events and single EQ-5D-5L items and the EQ-5D-5L summary score were demonstrated. All treatment groups significantly differed from the CDK4/6 inhibition subgroup in the EQ-VAS. Conclusions Compared to the EQ-5D-5L and QLQ-C30, the EQ-VAS showed a higher rate of deterioration after 8 weeks. Significant connections to certain metastatic locations were only detected in the EQ-VAS. The EQ-VAS is capable of reflecting the distinctive HRQoL profiles of different systemic treatments as well as the different aspects of HRQoL presented in the EQ-5D-5L. TTD with the EQ-VAS is an adequate mean of examining longitudinal development of HRQoL among breast cancer patients.

show abstract

Praktikabilität und Leistungsfähigkeit von E-Health-Anwendungen bei der Erhebung von Patient Reported Outcomes: Forschungsstand und -bedarf

Cited by 7 publications

References 43 publications

An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study

An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study

An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study (Preprint)

Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study

Contact Info

Product

Resources

About